Long-term open-label safety study of rizatriptan acute treatment in pediatric migraineurs.
OBJECTIVE
To evaluate the safety/tolerability of rizatriptan in the long-term acute treatment of migraine in pediatric patients.


BACKGROUND
Acute migraine treatment options for children are limited. A recent single-attack trial demonstrated that rizatriptan is effective in eliminating migraine headache pain in this population. We evaluated the long-term safety and efficacy of rizatriptan when used for intermittent acute treatment.


METHODS
Open-label study in pediatric migraineurs ages 12-17 years. Patients weighing <40 kg received rizatriptan (orally disintegrating tablet) 5 mg, and those weighing ≥40 kg received 10 mg. Patients could treat up to 8 mild/moderate/severe migraine attacks per month for up to 12 months. One dose of study medication was allowed in a 24-hour period.


RESULTS
A total of 674 patients were enrolled, and 606 patients were treated with study medication (N = 583 for 10 mg, N = 23 for 5 mg). The mean duration in the study was 292 days, and the mean number of doses of study medication taken was 20. Over the course of the study within 14 days post-any-dose, 66.0% (400) of the 606 treated patients had any adverse event, 2.3% (14) discontinued due to an adverse event, 2.6% (16) had a serious adverse event, and 23.4% (142) had a triptan-related adverse event. Of the 16 patients with serious adverse events within 14 days post-any-dose, the adverse events in 3 were considered drug-related; all 3 patient's adverse events were classified as serious only because they were associated with an overdose (use of >1 dose of study medication in a 24-hour period). The mean percentage of patient's attacks with pain freedom at 2-hours post-dose was 46.3%; this was relatively consistent over time (Months 1-3 = 43.7%, Months 4-6 = 51.9%, Months 7-9 = 49.9%, Months 10-12 = 49.5%).


CONCLUSIONS
Rizatriptan was generally safe and well tolerated in the long-term acute treatment of migraine in pediatric patients aged 12-17 years and demonstrated a consistent treatment effect over time.
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
David J
DJ
Hewitt
Savannah Neurology and Memorial University Medical Center, Savannah, GA, USA.
Eric
E
Pearlman
Helsinki University Central Hospital/Children's Hospital, Helsinki, Finland.
Mirja
M
Hämäläinen
Children's Hospital of the King's Daughters, Norfolk, VA, USA.
Donald
D
Lewis
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
Kathryn M
KM
Connor
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
David
D
Michelson
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
Paulette
P
Ceesay
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
Christopher
C
Assaid
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
Robert
R
Bachman
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
Lyn
L
Harper Mozley
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
Nicole
N
Dupre
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
Nancy
N
Strickler
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
Erin
E
Mahoney
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
Christopher
C
Lines
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
Tony W
TW
Ho
D000293:Adolescent; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy*; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*; D014363:Tryptamines / Q000009:adverse effects / Q000627:therapeutic use*
D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan